Gestational diabetes mellitus (GDM) is defi ned as a glucose intolerance that occurs for the fi rst time or it is fi rst identifi ed during pregnancy. Th e GDM etiology is multifactorial. It has not completely been established yet and several known risk factors may contribute to its onset. To date, there are no shared guidelines on the management and follow-up, especially regarding the lowincome countries. In this paper, we describe the state of art about epidemiology, physiopathology, diagnosis, and management of GDM. Moreover, we focus on the current state in low income countries trying to outline basis for further research.
Diabetes mellitus (DM) is one of the major actual public health issues consisting of chronic hyperglycemia which can damage body organs and systems (Karamanou et al. 2016) . Gestational diabetes mellitus (GDM) is a common metabolic complication in pregnancy, defi ned as a glucose intolerance identifying for the fi rst time during pregnancy (ReyesLopez et al. 2014) . GDM reveals usually between 24 and 28 weeks of gestation, without particular symptoms, but it should be screened as early as possible to avoid severe short-and long-term complications for mother, fetus or neonate (Hawryluk et al. 2015) . Insulin resistance in peripheral tissues and pancreatic beta-cells inadequacy to secrete insulin represent the double pathways involved in the hyperglycemia. On one side, during normal pregnancy, insulin sensitivity declines, leading to a higher insulin resistance in peripheral tissues, due to placental factors, progesterone and estrogen, having insulin-antagonistic eff ects (Reyes-Lopez et al. 2014) . On the other side, GDM occurs if pancreatic beta-cells are unable to face the increased insulin demand during pregnancy and the elevated glucagon-like peptide 1 (GLP-1) confi rms the abnormal insulin secretion (Reyes-Lopez et al. 2014) . In a physiological situation, a compensatory increased insulin secretion maintains a normal glucose homeostasis. To date, several pathophysiological mechanisms have been proposed, such as metabolic, infl ammatory, autoimmune, and genetic ones. It is likely that it is a multifactorial etiology (Baz et al. 2015; Issat et al. 2015) . As diabetes is oft en asymptomatic in the fi rst stages, the early diagnosis is solely biochemistry, while late untreated stages may include following symptoms: blurred vision, fatigue, frequent bladder, vagina and skin infections, polydipsia, polyuria, nausea and vomiting, and weight loss despite increased appetite (American Diabetes Association 2016) . Th e GDM management includes, other than therapy for diabetic women, also prevention and follows up of all at risk patients, not only during preg-nancy, but also in postpartum (Castorino and Jovanovic 2013) .
In this article, we review the epidemiology of GDM, the physiopathology and the management of this relevant disease with particular attention to the developing countries.
Epidemiology
GDM is the most common metabolic disorder of pregnant women with an estimated prevalence ranging from <1% to 28%. However, in the countries where universal screening is recommended, the percentage of pregnant women screened ranges from 10% to >90% (Jiwani et al. 2012) .Th e frequency of its occurrence depends, inter alia, on diagnostic methods, ethnicity, and body composition. In fact, many countries do not perform systematic screening for GDM, adopting diff erent guidelines or practices diverge from them. Again, some ethnic groups have long been associated with an increased risk of GDM and its prevalence seems particularly higher among women from South Asia and South East Asia than from Caucasian, African-American and Hispanic communities. In particular, GDM rate ethnicity is 11.9% for Asian and Pacifi c Island, 7.6% for American Indian, 5.6% for Black American, 8.4% for Hispanic, 5.4% for Non-Hispanic White, and 6.6% for other (Kim et al. 2013) . Th e prevalence of GDM in women who were born in Asian countries varied from 3.0% to 21.2%. Interestingly, the risk to develop GDM for South-Asian (Indian, Sri Lankan, Pakistani, Fijian Indian) women is higher than the SouthEast Asian (Cambodian, Vietnamese, Laotian, Th ai, Filipino, Malaysian) and the East-Asian (Chinese, South Korean, Taiwanese and Japanese) ones (Chu et al. 2009; Yuen and Wong 2015) . Among diff erent ethnicities, also mother and child outcomes have important variations. As for perinatal outcomes, newborns from Pacifi c Islander countries have higher rates of macrosomia, while children with Chinese backgrounds lower adverse outcomes (Yuen and Wong 2015) . From a maternal point of view, Asian pregnant women aff ected by GDM have a higher incidence of postpartum glucose intolerance and development of type 2 DM (Yuen and Wong 2015; Girgis et al. 2012) . Th e "non-Hispanic white" seems to have a lower rate of GDM recurrence (39%) compared with other ethnic groups (56%) (Schwartz et al. 1999) while, women from Hispanic or AfricanAmerican backgrounds with GDM have more likely developed hypertension post-partum (Yuen and Wong 2015) .
Physiopathology
In GDM, many biologic and molecular mechanisms of regulating glucose levels are involved. It has been demonstrated that inadequate decrease of the renal threshold for glucose (RTG) that is determined by the nephron's reabsorption capacity, play a role in the development of GDM. In fact, glucose is reabsorbed through sodium glucose transporters in the proximal tubules. However, during pregnancy, the renal glucose reabsorption capacity decreases due to reduced glucose transporter expression leading to lower glucose elimination (Klein et al. 2014) . From the molecular point of view, many regulators seem to play a role in the glucose homeostasis and GDM onset. During a normal pregnancy, the balance of T-helper cell activity is strongly shift ed toward an anti-infl ammatory profi le, characterized by Th -2 cytokines, which have a protective role in the fetalmaternal relationship (Abell et al. 2015) . Moreover, during pregnancy a fi ne balance occurs between proand anti-infl ammatory cytokines, needed for the normal development (Abell et al. 2015) . In particular, GDM seems to be linked to the down-regulation of adiponectin and anti-infl ammatory cytokines (e.g. IL-4, IL-10) and up-regulation of adipokines like leptin and pro-infl ammatory cytokines, implicated in insulin resistance [e.g. IL-6, TNF-α, adipocyte fatty acid-binding protein (AFABP)] (Abell et al. 2015) . In Table 1 , the main agents, involved in the GDM physiopathology, are reported (Qiu et al. 2004; Lewandowski et al. 2007; Mordwinkin et al. 2013; Lappas 2014; Abell et al. 2015; Iyidir et al. 2015; .
Risk factors
Many risk factors are involved in the development of GDM. First, mainly woman with previous GDM and/or high prevalence of glucose intolerance in the early postpartum period are at increased risk for its developing (Capula et al. 2014) . In fact, it seems that they have high catalase levels, indicating the potential oxidative stress eff ects on postpartum glycemic status related to glucose intolerance (Roca-Rodriguez et al. 2014) . Moreover, women with prior GDM have more frequently glutamic acid decarboxylase (GAD) autoantibodies (Lundberg et al. 2015) . Th us, metabolic status can represent a risk factor, in particular, high levels of fasting plasma glucose (FPG), triglyceride, total cholesterol, low density lipoprotein (LDL), fasting insulin (FINS), and homeostasis model assessment of insulin resistance (HOMA-IR) and low levels of high density lipoprotein (HDL), are considered independent risk factors for GDM (Shuang and Huixia 2014) . Interestingly, low levels of 25-hydroxyvitamin D [25(OH)D] at fi rst trimester is another independent risk factor for developing GDM. It is associated with insulin resistance at second trimester (Lacroix et al. 2014) . Growing evidence suggests a role of environmental chemicals, as arsenic, phthalates, bisphenol A, metals NOx, SO 2, and O 3, in the development of GDM (Robledo et al. 2015; Shapiro et al. 2015) . By contrast, moderate coff ee and tea intake may have a protective eff ect (Hinkle et al. 2015) . Women with a history of infertility and polycystic ovary syndrome (PCOS) seem to be more aff ected by GDM (Ashrafi et al. 2014) . Furthermore, the GDM risk is two-fold higher in women undergoing assisted reproductive technology (ART) compared with women who conceived spontaneously. Another important risk factor for GDM is the use of progesterone during pregnancy (Ashrafi et al. 2014) . At last, an issue that is still to be clarifi ed is the genetic susceptibility. To date, some studies have shown pathological involvement of single nucleotide polymorphisms (SNPs). In particular, SNP for ENPP1 gene both homozygous for A allele and heterozygous is associated with GDM. Moreover, AA homozygous genotype, associated with age (≥ 35 years) and pre- Table 1 Th e main factors involved in GDM physiopathology.
Name Description
Adiponectin Adiponectin is a plasma protein secreted from adipose tissue and it is decreased in obesity. It is an insulinsensitizing, anti-infl ammatory and anti-atherogenic adipokine that stimulates glucose uptake in skeletal muscle and reduces hepatic glucose production through AMP-activated protein kinases. Down-regulation of adiponectin may predict GDM several months before clinical diagnosis, independent of BMI status. Low levels of adiponectin exacerbates insulin resistance and correlates with β cell dysfunction.
Adipokine Adipokine secretion contributes to glucose homeostasis in pregnancy by direct (insulin secretion regulation and insulin sensitivity) and indirect (adipogenesis regulation and immune cells chemoattraction) mechanisms. Adipokine secretion increase insulin resistance.
TNF-α IL-6
TNF-α and IL-6 are produced by placenta, adipose tissue monocytes and macrophages and lead to insulin resistance. In GDM, particularly during second and third trimester, oxidative stress and infl ammation induced by hyperglycemia, further increase levels of TNF-α and IL-6.
Leptin
Leptin is a hormone protein released by adipose tissue and suppresses insulin secretion from pancreatic beta cells. Moreover, leptin is involved in appetite control, body weight and composition and energy consumption. Increased leptin synthesis in GDM stimulates production of pro-infl ammatory cytokines such as IL-6 and TNF-α, which further enhances leptin production.
AFABP
Adipocyte fatty acid-binding protein belongs to the fatty-acid binding proteins family and is highly expressed in adipocytes, macrophages and endothelial cells. Serum AFABP levels are increased in the third trimester and result up-regulated in GDM and seems to induce insulin resistance.
Resistin
Resistin is a hormone expressed in monocytes and macrophages, and adipocytes. It seems to have a role in insulin resistance during pregnancy, without a central role in glucose homeostasis and development of GDM.
Visfatin
Visfatin is highly expressed in visceral adipose tissue, promotes adipogenesis and has insulin-mimetic eff ects. Visfatin is reported to be both decreased and increased in GDM.
Fetuin A Fetuin A is a blood proteins produced by the liver and play a role in the development of insulin resistance and the metabolic changes in GDM. It is increased during pregnancy and decreased aft er delivery.
EPC
Decreased levels of maternal circulating endothelial progenitor cells increase soluble adhesion molecules adhesion in maternal blood, decrease expression of superoxide dismutase and increase endothelial nitric oxide synthase expression in maternal and cord blood leading increased oxidative stress and endothelial dysfunction women and fetuses.
Vitamin D Low vitamin D is implied in the etiology of obesity, insulin resistance and diabetes mellitus probably due to a chronic low-grade infl ammation mechanisms. Vitamin D defi ciency is common in pregnancy, and may contribute to abnormal glycemic control. Reactive oxygen species
Oxidative damages cause mitochondrial dysfunction and impair antioxidant mechanisms. Reactive oxygen species have an important role in pathogenesis of almost all chronic metabolic diseases and in GDM they lead insulin resistance. GDM -gestational diabetes mellitus; BMI -body mass index; TNF-α -tumor necrosis factor-α; IL-6 -interleukin-6; AFABPadipocyte fatty acid-binding protein; EPC -endothelial progenitor cells gestational high body weight and body mass index (BMI) increased signifi cantly the risk of impaired glucose tolerance and GDM (Tarquini et al. 2015) .
Complications
GDM complications may occur on newborns or mothers. In fact, newborns can be aff ected by birth defects, impaired intrauterine fetal growth, and higher incidence of premature births and greater percentage of the intrauterine fetus death (Hawryluk et al. 2015) . In particular, macrosomia is the main adverse pregnancy outcome due to the fetal hyperinsulinism, developed in response to maternal hyperglycemia. Furthermore, intrauterine exposure to GDM is linked to development of hypertension, obesity, and type 2 DM in children (Blue et al. 2015) . On the other side, mothers may face complications in shortor long-term. Short-term, they may show high stress level, low sleep quality, and impaired cognitive functions (Hayase et al. 2014; Keskin et al. 2015) . Moreover, they can develop thyroiditis, renal diseases, and type 2 DM (Beharier et al. 2015; Hopmans et al. 2015; Maleki and Tavosi 2015) . Long-term eff ects, instead, are subclinical atherosclerosis, arterial hypertension, and cardiovascular disease (CVD) (Li et al. 2014; Oliveira et al. 2015) . Th e association between GDM and CVD is so strong that in the absence of other recognized cardiovascular risk factors, such as smoking, obesity or chronic hypertension, GDM represents a useful marker of raised CVD risk among women with BMI between 25 and 29 (Fadl et al. 2014 ).
Diagnosis
It is well known that early diagnosis is crucial to ensure the most eff ective treatment and lower consequences for mother and newborn. Identifying pregnant women with risk factors for GDM based on the clinical suspicion is a popular approach. Moreover, pregnant women without known DM should be screened for DM aft er 24 weeks of gestation, including glucose monitoring and lifestyle educations (Garrison 2015) . World Health Organization (WHO) established criteria for the GDM diagnosis and the prevention, but to date, many strategies exist addressed to this issue (Aktun et al. 2015) . Different structured checklists to identify risk women have been developed and though their eff ectiveness has to be still assessed (Fawole et al. 2014) . In Sherbrooke, Regional Committee proposed GDM screening during the fi rst trimester for all pregnant women based on a 50 g glucose challenge test (50 g GCT), followed directly by capillary self-monitoring blood glucose (SMBG) at home (Allard et al. 2015) . Th e Societe Francophone du Diabete (SFD) and the College national des Gynecologues et Obstetriciens Français (CNGOF) proposed a selective screening based on risk factors rather than universal screening, measuring fasting blood glucose at the fi rst visit for women with risk factors (Vambergue 2013) .
Th ree methods are commonly used for GDM screening: fasting plasma glucose (FPG), two-step 50 g glucose challenge test (GCT), and 75 g glucose tolerance test (GTT). Although there is no a common opinion, 75 g GTT seems to be preferred for GDM screening in the fi rst trimester (Yeral et al. 2014) . Th e International Association of Diabetes in Pregnancy Study Groups (IADPSG) have developed recommendations for the use of a 75 g, 2-h GTT, ≥1 elevation diagnosing GDM, with follow thresholds: fasting plasma glucose ≥5.1 mmol/l (92 mg/dl), 1 h ≥10 mmol/l (180 mg/dl), and 2 h ≥8.5 mmol/l (153 mg/dl) (Coustan 2014) . However, USA, European countries, and Australia have developed their own guidelines based on the maternal risk of subsequent diabetes, on arbitrary statistics, or on non-pregnant women. Th e International Association of Diabetes and Pregnancy Study Group, for the fi rst time, proposed new diagnostic criteria for gestational diabetes mellitus, based also on perinatal outcome (Houshmand et al. 2013) . Th is topic is still controversial. On one side, some authors suggest to use estimated fetal weight (EFW) from ultrasonography at 18 to 22 weeks, to predict GDM and newborn macrosomia (Liao et al. 2014) . On the other side, other authors prompt that EFW at 18 to 22 weeks does not predict the onset of GDM, but large for gestational age (LGA) (Liao et al. 2014) .
Other markers are much less used and with poor scientifi c evidence. For example, the utility of hemoglobin A1c (HbA1c) that is a widely used in diagnosing type 2 DM is not yet established for GDM (Kwon et al. 2015) . Interestingly, glycated albumin is not infl uenced by iron defi ciency and therefore, it might be a better indicator of glycemic control in patients with GDM and pregnant women with diabetes mellitus (Hashimoto and Koga 2015) . Moreover, highsensitive C-reactive protein (hs-CRP) and maternal serum sex hormone binding globulin (SHBG) are less used but can be important early predictors of GDM as well uric acid, creatinine, and albumin (Maged et al. 2014) . Measurement of serum PlGF at 11-14 weeks improves the performance of early screening for GDM (Eleft heriades et al. 2014 ). Yilmaz and colleagues have suggested also the neutrophil-to-lym-phocyte ratio (NLR) as an independent predictor of GDM development (Zhu et al. 2015) . Finally, in the next future, miRNA expressed in GDM could serve as earlier predictive markers (Zhu et al. 2015) . In particular, Dicer and Drosha are the two major enzymes in the miRNA biogenesis process with evidence of up-regulation in GDM patients (Rahimi et al. 2015) .
Management: prevention, therapy and follow-up Prevention
GDM prevention is not only crucial for mother and newborn health, but also for reducing the economic burden of this disease (Dall et al. 2014) . All health institutions recommend lifestyle interventions that include exercise and healthy diet, both to prevent and manage GDM (Artal 2015) . Moderate and controlled physical exercise has a powerful potential to help blood glucose control with benefi t in prevention and treatment (Sanabria-Martinez et al. 2015) . To date, there are no guidelines available for exercise in GDM. Th e recommendation of both aerobic and resistance exercises of a moderate intensity, a minimum of three times a week for 30-60 minutes as suggested by some authors (Padayachee and Coombes 2015) , is still controversial (Ruchat and Mottola 2013) . Although a specifi c diet does not exist, the conventional diet approach to prevent and fi ght GDM provides carbohydrate restriction (Hernandez et al. 2014 ). Interestingly, Mediterranean diet pattern seems to be associated with better glucose tolerance and lower incidence of GDM (Karamanos et al. 2013) . Moreover, as short sleep duration and sleep disorders are risk factors for poor glycemia control, educating women on healthy sleep and screening for and treating sleep disorders during pregnancy may have a role in optimizing gestational diabetes prevention (Twedt et al. 2015) . In women with a history of GDM or PCOS, in addition to lifestyle, also metformin seems to be highly eff ective in reducing progression to diabetes due to its metabolic, endocrine, vascular, and antiinfl ammatory eff ects (Khattab et al. 2011; Aroda et al. 2015; Poomalar 2015) .
Th erapy
Th e aim of GDM treatment following WHO criteria is to normalize blood glucose level in order to reduce risk of the adverse maternal and neonatal complications, such as cesarean section, polyhydramnios, preterm delivery, neonatal intensive care, and high neonatal weight (Aktun et al. 2015) . Th e fi rst-line therapy is insulin, which is not only safe but also useful to restore placental endothelial function (Sobrevia et al. 2015) . In fact, it was demonstrated that in diet-treated GDM, although maternal and newborn glucose levels were normal, fetoplacental vascular dysfunction lasted. In these cases, insulin addiction may restore the normal metabolic condition of the vascular network, promoting the health of the growing fetus, newborn, and mother (Sobrevia et al. 2015) . In addition, insulin treatment of mild GDM has been associated with neonatal benefi ts, while no reduction in childhood obesity or metabolic dysfunction in the off spring has been observed (Landon et al. 2015) . Th e main insulin therapy limitations are hypoglycemia and weight gain (Mirzamoradi et al. 2015) . Moreover, it could represent a complicated therapeutic option due to the diffi culty in administration with multiple daily injections (Magon and Seshiah 2011) . Most insulin analogues (insulin lispro, aspart and detemir) are also considered safe and with comparable results in pregnancy (Simmons 2015) . Interestingly, subcutaneous insulin with continuous glucose monitoring system may play a role in women requiring higher dosage (Poomalar and Rangaswany 2013) .
Currently, there is growing interest in oral drugs as glyburide (second-generation sulfonylurea) and metformin (biguanide) due to the better patients' adherence and their safety, eff ectiveness and cheapness (Magon and Seshiah 2011) . In particular, metformin seems to be eff ective and safe for the treatment GDM, particularly for overweight or obese women and patients with PCOS, due to maternal weight lowering, better neonatal outcomes, reduction of early pregnancy loss, and fetal growth restriction (Lautatzis et al. 2013) . Interestingly, although there are no guidelines for the continuous use of metformin in pregnancy, teratogenic eff ects, intra-uterine deaths or developmental delays have been not demonstrated. However, in patients with multiple risk factors for insulin resistance, it is not enough and insulin supplementation is necessary (Lautatzis et al. 2013) . Particular attention has to be paid to glyburide and metformin due to their altered pharmacokinetics during pregnancy and their ability to cross the placenta (Ryu et al. 2014) . Moreover, metformin seems to be associated with gastrointestinal adverse eff ects, while glibenclamide is associated with hypoglycemia and weight gain (Simmons 2015) .
Follow up
Women with gestational diabetes mellitus need a continuum care before, during, and aft er pregnancy for optimal management of hyperglycemia, including education and lifestyle modifi cation (Castorino and Jovanovic 2013). Self-monitoring of blood glucose has been found more eff ective than the clinical glucose blood checking due to its higher ease and frequency (Magon and Seshiah 2011) . If GDM is correct and regular, pregnancy can safely get to 39 weeks, while, if glycemic control is poor or there are others indicators for delivery, such as maternal medical conditions, obstetric complications or major congenital anomalies, cesarean delivery should be considered preferably in women with an estimated fetal weight greater than 4500 g (Garrison 2015 ). Since women with GDM have a 7-fold higher risk of developing diabetes, they should be screened 6 to 12 weeks postpartum and every 3 years thereaft er (Olesen et al. 2014 ). However, follow-up rates are poor and usually mothers are not completing recommended postnatal screening aft er GDM (Kilgour et al. 2015) . Th e causes of this low compliance are not studied or understood but certainly a quality communication and information is crucial to achieve an eff ective strategy to complete the recommended postnatal GDM followup. (Kilgour et al. 2015) . Furthermore, women should receive education on the long-term risk of type 2 DM and should be encouraged to breastfeed, engage in regular physical activity, and select a highly eff ective contraceptive method in preparation for subsequent pregnancy (Castorino and Jovanovic 2013).
GDM in low-income countries
To date, little is known about GDM in low-income countries, particularly in Africa. It is clear that it is essential to fi nd cheap and applicable screening and treatment options.
Prevalence and risk factors of GDM in sub-Saharan Africa seems to be high up to about 14% and heterogeneous (Mwanri et al. 2015) . Interestingly, prevalence of GDM is higher in women with previous stillbirth, family history of type 2 DM, and medium upper arm circumference (MUAC) above 28 cm, while women living in rural areas showed signifi cantly lower prevalence (Anzaku and Musa 2013; Mwanri et al. 2015) . In low-income countries, cheaper treatments alternative to insulin are metformin and glibenclamide but authors have suggested as more effective and acceptable strategy a prevention, as an appropriate diet and physical exercise in order to reduce the short-and long-term GDM related complications (Coetzee 2009 ). More and more studies are necessary to understand this issue and fi nd adequate solutions.
Conclusions
GDM is a disease with high health and economic costs avoidable or reducible by prevention, screening, and right management (Danyliv et al. 2015) . First of all, woman information and education is crucial in order to reach an eff ective GDM self-management, especially in low-income countries, where therapy resources are limited. In particular, in the Th ird World, resources should be literacy appropriate with photographs and simple text, including culturally appropriate foods and information. At the same time, new and more research eff orts should be done in order to improve knowledge and GDM management. Th e priority is to standardize diagnosis criteria based on the plasma glucose level and/or other parameters and identifi ed, if possible, the threshold for the pathological hyperglycemia aft er 24 weeks of gestation. To achieve this goal, it is crucial to even methods such as sample type (serum, plasma or culture supernatant), sample source (maternal, placental, cord), and assay (e.g. enzyme-linked immunosorbent assays, chemiluminescent immunoassay, and radioimmunoassay) and to adjust the results considering major confounders, including maternal age, ethnicity, smoking status, BMI, and glucose levels. Furthermore, it is relevant to clarify and assess the validity and strength of new possible markers, as 25(OH)D, miRNA, infl ammatory, and metabolic markers as well as risk factors as PCOS, ART and exposures to NOx and SO 2 . Finally, to improve women compliance, it will be necessary to simplify the "patient life" with cost-eff ective solutions in the medicine care.
